Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Medicine Developer SalioGen Therapeutics Raises $115M

NEW YORK — SalioGen Therapeutics said on Wednesday that it has raised $115 million through an oversubscribed and up-sized Series B financing round.

The round was co-led by GordonMD Global Investments and EPIQ Capital Group with participation from new investors Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, the RD Fund, and others. Existing investor PBM Capital also participated.

SalioGen is developing medicines for inherited diseases based on a technology called exact DNA integration technology, or EDIT, which uses a mammal-derived enzyme called saliogase to integrate DNA into defined locations in the genome. The company's pipeline includes early-stage preclinical programs in a range of eye, lung, liver, heart, and kidney disorders.

Cambridge, Massachusetts-based SalioGen said that it will use the newly raised cash to continue work on its therapeutic platform, expand its staff, and establish manufacturing and automation capabilities.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.